Effective management of dyslipidaemia among patients with cardiovascular risk: Updated recommendations on identification and follow-up

European Journal of General Practice

Volumn 11, Issue 2, 2005, Pages 68-75

  Hobbs, F D Richard ^a   Hoes, Arno W ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular risk; Guidelines; Hypertension; Low density lipoprotein cholesterol; Primary care

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHYTOSTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG POTENTIATION; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPOLYSIS; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; MYALGIA; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 27544454587     PISSN: 13814788     EISSN: None     Source Type: Journal    
DOI: 10.3109/13814780509178241     Document Type: Article

References (63)

1. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982;248(12):1465-77.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987;257(16): 2176-80.
3. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five year follow-up of the seven countries study. JAMA 1995;274(2):131-6.
4. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet1990;335(8692): 765-74.
5. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease. JAMA 2003;290:891-7.
6. Khot UN, Khot MB, Bayzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837-47.
8. The health benefits of smoking cessation: a report of the surgeon general. 90-8416. 1990. Rockville, Md, US Dept of Health and Human Services.
9. Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet 1990;336(8711):370-1.
10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
12. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001;9(Suppl 4): S326-34.
13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
14. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24(17):1601-10.
15. Simoons ML. [Cholesterol-lowering therapy; a recommendation from the Health Council]. Ned Tijdschr Geneeskd 2000;144(51):2442-4.
16. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106(16):2055-60.
17. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357(9256):577-81.
18. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291(9):1071-80.
19. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Comparison of intensive and moderate lipid lowering with statins after coronary syndromes. N Engl J Med 2004;350(15): 1495-504.
20. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70(7):733-7.
21. Frick MH, Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Manttari M. HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study. Drugs 1990;40(Suppl 1): 7-12.
22. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;11(1):32-47.
23. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8(6):737-41.
24. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77(14):1179-84.
25. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36.
26. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
27. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361:777-80.
28. WHO. World Health Report. 2002.
29. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357(9261):995-1001.
30. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82(1): 61-5.
31. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003;89:417-21.
32. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160(4):459-67.
33. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111: 185-91.
34. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164(4): 208-11.
35. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in chronic disease. Annu Rev Nurs Res 2000;18:48-90.
36. Ballantyne CM. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction. Am Heart J 2004;148(Suppl 1):S3-8.
37. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-39.
38. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107(3):499-511.
39. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000; 101(1):E16-22.
40. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000;55(12):987-99.
41. Walden CE, Retzlaff BM, Buck BL, McCann BS, Knopp RH. Lipoprotein lipid response to the National Cholesterol Education Program step II diet by hypercholesterolemic and combined hyperlipidemic women and men. Arterioscler Thromb Vasc Biol 1997;17: 375-82.
42. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
43. Arntzenius AC, Kromhout D, Barth JD, Reiber JH, Bruschke AV, Buis B, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N Engl J Med 1985; 312:805-11.
44. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.
45. Welty FK, Stuart E, O'Meara M, Huddleston J. Effect of addition of exercise to therapeutic lifestyle changes diet in enabling women and men with coronary heart disease to reach Adult Treatment Panel III low-density lipoprotein cholesterol goal without lowering high-density lipoprotein cholesterol. Am J Cardiol 2002;89:1201-304.
46. Koren M, Hunninghake D, on behalf of the ALLIANCE investigators. Comparison of clinical outcomes in managed care patients with coronary heart disease treated in aggressive lipid lowering programs using atorvastatin versus usual care. Program and abstracts from the American College of Cardiology 53rd Annual Scientific Session; March 7-10, 2004; New Orleans, Louisiana. Late Breaking Clinical Trials I.
47. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18(10):1569-82.
48. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91 (5A):C11-7.
49. Libby P, Aikawa M. Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol 2003;26(Suppl 1):I11-4.
50. Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, et al. Moderate dose, three-drug therapy with macin, lovastatin and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia. Am J Cardiol 1997;80:111-5.
51. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release macin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7.
52. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24.
53. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.
54. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double- blind trial. Circulation 2003;107:2409-15.
55. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326(7404):1419.
56. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995332(17):1125-31.
57. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-25.
58. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7.
59. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87(7):819-22.
60. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-50.
61. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6): 393-403.
62. DeBusk RT, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120:721-9.
63. McClure JB. Are biomarkers useful treatment aids for promoting health behavior change? An empirical review. Am J Prev Med 2002;22(3):200-7.